| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Helen Blair Simpson, Edna B Foa, Michael R Liebowitz, Jonathan D Huppert, Shawn Cahill, Michael J Maher, Carmen P McLean, James Bender, Sue M Marcus, Monnica T Williams, Jamie Weaver, Donna Vermes, Page E Van Meter, Carolyn I Rodriguez, Mark Powers, Anthony Pinto, Patricia Imms, Chang-Gyu Hahn, Raphael Campea. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA psychiatry. vol 70. issue 11. 2014-01-09. PMID:24026523. |
cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. |
2014-01-09 |
2023-08-12 |
Not clear |
| Sergi Mas, Patricia Gassó, Miquel Bernardo, Amalia Lafuent. Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 23. issue 4. 2014-01-06. PMID:22612990. |
risperidone is a potent antagonist of both dopamine and serotonin receptors. |
2014-01-06 |
2023-08-12 |
human |
| Veit Roessner, Katja Schoenefeld, Judith Buse, Stephan Bender, Stefan Ehrlich, Alexander Müncha. Pharmacological treatment of tic disorders and Tourette Syndrome. Neuropharmacology. vol 68. 2013-09-09. PMID:22728760. |
in more severe cases the combination of risperidone and a selective serotonin reuptake inhibitor should be given. |
2013-09-09 |
2023-08-12 |
Not clear |
| Caitlin E McOmish, Alena Lira, James B Hanks, Jay A Gingric. Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 37. issue 13. 2013-08-26. PMID:22871913. |
wild-type (wt) and 5-ht(2a) knockout (ko) mice treated with haloperidol, clozapine, and risperidone were assessed for locomotor activity and catalepsy. |
2013-08-26 |
2023-08-12 |
mouse |
| Caitlin E McOmish, Alena Lira, James B Hanks, Jay A Gingric. Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 37. issue 13. 2013-08-26. PMID:22871913. |
interestingly, 5-ht(2a) ko mice were cataleptic following haloperidol and risperidone, but did not respond to clozapine's locomotor-suppressing effects. |
2013-08-26 |
2023-08-12 |
mouse |
| Minako Tajiri, Atsuko Hayata-Takano, Kaoru Seiriki, Katsuya Ogata, Keisuke Hazama, Norihito Shintani, Akemichi Baba, Hitoshi Hashimot. Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders. Journal of molecular neuroscience : MN. vol 48. issue 3. 2013-04-19. PMID:22843252. |
the serotonin 5-ht(7) receptor has been linked to various psychiatric disorders, including schizophrenia, anxiety and depression, and is antagonized by antipsychotics such as risperidone, clozapine and lurasidone. |
2013-04-19 |
2023-08-12 |
mouse |
| Herbert Y Meltzer, Helio Elkis, Kimberly Vanover, David M Weiner, Daniel P van Kammen, Perry Peters, Uli Hacksel. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophrenia research. vol 141. issue 2-3. 2013-03-19. PMID:22954754. |
pimavanserin, a selective serotonin (5-ht)2a-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. |
2013-03-19 |
2023-08-12 |
Not clear |
| Herbert Y Meltzer, Helio Elkis, Kimberly Vanover, David M Weiner, Daniel P van Kammen, Perry Peters, Uli Hacksel. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophrenia research. vol 141. issue 2-3. 2013-03-19. PMID:22954754. |
risperidone (ris), produce more extensive blockade of brain serotonin (5-ht)(2a) than dopamine (da) d(2) receptors. |
2013-03-19 |
2023-08-12 |
Not clear |
| Yavuz Selvi, Abdullah Atli, Adem Aydin, Lutfullah Besiroglu, Pinar Ozdemir, Osman Ozdemi. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Human psychopharmacology. vol 26. issue 1. 2013-03-08. PMID:21308781. |
the comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. |
2013-03-08 |
2023-08-12 |
Not clear |
| Yavuz Selvi, Abdullah Atli, Adem Aydin, Lutfullah Besiroglu, Pinar Ozdemir, Osman Ozdemi. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Human psychopharmacology. vol 26. issue 1. 2013-03-08. PMID:21308781. |
to investigate the comparative efficacy of aripiprazole and risperidone as augmenting agents in the treatment of obsessive-compulsive disorder (ocd) patients who did not show a ≥35% decrease in the yale-brown obsessive-compulsive scale (y-bocs) after 12-week monotherapy with selective serotonin reuptake inhibitors (ssris). |
2013-03-08 |
2023-08-12 |
Not clear |
| W V Vieweg, R A Leadbette. Polydipsia-hyponatraemia syndrome : epidemiology, clinical features and treatment. CNS drugs. vol 7. issue 2. 2013-01-23. PMID:23338131. |
these interventions require an experienced and dedicated multidisciplinary staff.a number of pharmacological treatments have been assessed for phs including the combination of lithium and phenytoin, demeclocycline, propranolol, ace inhibitors, selective serotonin (5-hydroxytryptamine; 5-ht) reuptake inhibitors, typical antipsychotic drugs, clozapine and risperidone. |
2013-01-23 |
2023-08-12 |
Not clear |
| Zofia Rogóż, Marcin Kabzińsk. Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacological reports : PR. vol 63. issue 6. 2012-11-07. PMID:22358101. |
way100635 (a 5-ht(1a) receptor antagonist) inhibited the effects induced by co-administration of ads and risperidone. |
2012-11-07 |
2023-08-12 |
mouse |
| Zofia Rogóż, Marcin Kabzińsk. Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacological reports : PR. vol 63. issue 6. 2012-11-07. PMID:22358101. |
the obtained results indicate that a low dose of risperidone enhances the activity of ads in an animal model of depression, and that, among other mechanisms, 5-ht(1a) receptors may play a role in these effects. |
2012-11-07 |
2023-08-12 |
mouse |
| Pietro Gareri, Pasquale De Fazio, Mariagrazia Stilo, Guido Ferreri, Giovambattista De Sarr. Conventional and atypical antipsychotics in the elderly : a review. Clinical drug investigation. vol 23. issue 5. 2012-10-02. PMID:17535043. |
newer antipsychotics, such as clozapine, olanzapine, risperidone, quetiapine and ziprasidone, have a different receptor-binding profile, interacting with both d and 5-ht receptors; they less frequently cause eps and are better tolerated in the elderly. |
2012-10-02 |
2023-08-12 |
Not clear |
| L J Herberg, A M Montgomery, A J Grottic. α 2-Adrenoreceptor antagonism may contribute to the atypical properties of risperidone: experimental support for the Nutt case. Journal of psychopharmacology (Oxford, England). vol 9. issue 3. 2012-10-02. PMID:22297769. |
the therapeutic efficacy and reduction in side effects claimed for new antischizophrenic drugs such as clozapine and risperidone have been ascribed to their heightened affinity for serotonin 5-ht(2) receptors rather than d-2 receptors. |
2012-10-02 |
2023-08-12 |
Not clear |
| L J Herberg, A M Montgomery, A J Grottic. α 2-Adrenoreceptor antagonism may contribute to the atypical properties of risperidone: experimental support for the Nutt case. Journal of psychopharmacology (Oxford, England). vol 9. issue 3. 2012-10-02. PMID:22297769. |
we have confirmed that at least one atypical property of risperidone (a rapid decrement in its ability to depress self-stimulation) can be partly prevented by an α(2)-adrenoreceptor agonist (clonidine) but not by a 5-ht( 2) receptor agonist (doi). |
2012-10-02 |
2023-08-12 |
Not clear |
| Sandip Shah, Dipti Josh. Tolerability and efficacy of paliperidone ER compared to olanzapine in the treatment of schizophrenia: A randomized, double-blind, multicentric trial. Industrial psychiatry journal. vol 20. issue 1. 2012-10-02. PMID:22969177. |
paliperidone is an active metabolite of risperidone and actss through a combination of central dopamine type 2 (d2) and serotonin type 2 (5ht2a) receptor antagonism. |
2012-10-02 |
2023-08-12 |
Not clear |
| Magdalena Kozielska, Martin Johnson, Venkatesh Pilla Reddy, An Vermeulen, Cheryl Li, Sarah Grimwood, Rik de Greef, Geny M M Groothuis, Meindert Danhof, Johannes H Proos. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharmaceutical research. vol 29. issue 7. 2012-10-01. PMID:22437487. |
pharmacokinetic-pharmacodynamic modeling of the d₂ and 5-ht (2a) receptor occupancy of risperidone and paliperidone in rats. |
2012-10-01 |
2023-08-12 |
rat |
| Magdalena Kozielska, Martin Johnson, Venkatesh Pilla Reddy, An Vermeulen, Cheryl Li, Sarah Grimwood, Rik de Greef, Geny M M Groothuis, Meindert Danhof, Johannes H Proos. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharmaceutical research. vol 29. issue 7. 2012-10-01. PMID:22437487. |
a pharmacokinetic-pharmacodynamic (pk-pd) model was developed to describe the time course of brain concentration and dopamine d₂ and serotonin 5-ht(2a) receptor occupancy (ro) of the atypical antipsychotic drugs risperidone and paliperidone in rats. |
2012-10-01 |
2023-08-12 |
rat |
| Louise Witten, Benny Bang-Andersen, Søren Møller Nielsen, Silke Miller, Claus Tornby Christoffersen, Tine Bryan Stensbøl, Lise Tøttrup Brennum, Jørn Arn. Characterization of [³H]Lu AE60157 ([³H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline) binding to 5-hydroxytryptamine₆ (5-HT₆) receptors in vivo. European journal of pharmacology. vol 676. issue 1-3. 2012-05-18. PMID:22155399. |
the striatal binding of [(3)h]lu ae60157 was fully displaced by selective 5-ht(6) receptor antagonists (sb-742457; lu ae58054) and antipsychotics known to inhibit the binding of 5-ht(6) receptors in vitro (clozapine; olanzapine; sertindole), but was not displaced by antipsychotics lacking high 5-ht(6) receptor affinities (risperidone; haloperidol; quetiapine). |
2012-05-18 |
2023-08-12 |
mouse |